These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 20408739

  • 1. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N, Wong BS, Camilleri M.
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [Abstract] [Full Text] [Related]

  • 2. 5-HT4 receptor agonists: similar but not the same.
    De Maeyer JH, Lefebvre RA, Schuurkes JA.
    Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
    [Abstract] [Full Text] [Related]

  • 3. Prucalopride: a new drug for the treatment of chronic constipation.
    Tack J.
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):337-43. PubMed ID: 19673621
    [Abstract] [Full Text] [Related]

  • 4. Translating 5-HT receptor pharmacology.
    Sanger GJ.
    Neurogastroenterol Motil; 2009 Dec; 21(12):1235-8. PubMed ID: 19906028
    [Abstract] [Full Text] [Related]

  • 5. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
    Sanger GJ, Alpers DH.
    Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C.
    Int J Clin Pract; 2002 Mar; 56(1):47-51. PubMed ID: 11831835
    [Abstract] [Full Text] [Related]

  • 7. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ.
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
    Kamm MA.
    Eur J Surg Suppl; 2002 Oct; (587):10-5. PubMed ID: 16144196
    [Abstract] [Full Text] [Related]

  • 9. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ.
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [Abstract] [Full Text] [Related]

  • 10. Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.
    Becker DP, Flynn DL, Shone RL, Gullikson G.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5509-12. PubMed ID: 15482914
    [Abstract] [Full Text] [Related]

  • 11. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.
    Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, Müller-Lissner S, Quigley EM, Schuurkes J, De Maeyer JH, Stanghellini V.
    Aliment Pharmacol Ther; 2012 Apr 15; 35(7):745-67. PubMed ID: 22356640
    [Abstract] [Full Text] [Related]

  • 12. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs.
    Mikami T, Ochi Y, Suzuki K, Saito T, Sugie Y, Sakakibara M.
    J Pharmacol Exp Ther; 2008 Apr 15; 325(1):190-9. PubMed ID: 18198343
    [Abstract] [Full Text] [Related]

  • 13. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M, Pace F.
    Dig Dis; 2006 Apr 15; 24(1-2):59-69. PubMed ID: 16699264
    [Abstract] [Full Text] [Related]

  • 14. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł, Thor PJ.
    Acta Pol Pharm; 2009 Apr 15; 66(5):447-60. PubMed ID: 19894640
    [Abstract] [Full Text] [Related]

  • 15. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 15; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 16. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD.
    Aliment Pharmacol Ther; 2004 Nov 15; 20 Suppl 7():3-14. PubMed ID: 15521849
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T, Komada T, Sugimoto H, Suzuki K, Ohmi T, Kimura N, Naganeo R, Nakata E, Nakatani K, Toga T, Eda H, Sakakibara M.
    Eur J Pharmacol; 2009 May 01; 609(1-3):5-12. PubMed ID: 19285067
    [Abstract] [Full Text] [Related]

  • 18. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F, Tonini M.
    Drugs; 2001 May 01; 61(3):317-32. PubMed ID: 11293643
    [Abstract] [Full Text] [Related]

  • 19. [New therapeutical approaches for treatment of irritable bowel syndrome].
    Siegert F, Nieber K.
    Med Monatsschr Pharm; 2010 Aug 01; 33(8):285-92; quiz 293-4. PubMed ID: 21189648
    [Abstract] [Full Text] [Related]

  • 20. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.
    Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN.
    Am J Gastroenterol; 2002 Jan 01; 97(1):194-7. PubMed ID: 11811166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.